AMH

The AMH hormone is a biomarker that directly evaluates ovarian reserve. Its level in the blood provides information about the existing follicle pool and enables the medical interpretation of reproductive potential.

The use of AMH levels in infertility assessment makes it possible to detect decreased ovarian reserve at an early stage. The value ranges demonstrate age-related changes and support clinical decision-making processes.

The principles of performing the AMH test include cycle-independent sampling and taking into account measurement differences between laboratories. This approach provides a standardized assessment that increases the reliability of the results.

Planning treatment according to the AMH level makes it possible to individualize controlled ovarian stimulation protocols. In this way, the risks of excessive or insufficient response are reduced and the likelihood of success in assisted reproductive treatments increases.

What Is AMH?

AMH (Anti-Müllerian Hormone) is a hormone used to evaluate ovarian reserve in women. It is secreted by the small follicles in the ovaries, and its level in the blood reflects a woman’s reproductive potential. The AMH test is frequently used in assisted reproductive treatments such as in vitro fertilization (IVF), in determining the risk of early menopause, and in the diagnosis of polycystic ovary syndrome (PCOS).

What is the main role of the AMH hormone in the body?

Within the ovary, AMH has two very cleverly designed main functions. It acts almost like a “reserve protection” mechanism.

Its first function is to slow down the awakening of the dormant primordial eggs (primordial follicles). It exerts almost a “brake” effect on these eggs. In this way, it prevents the limited reserve a woman is born with from being consumed too quickly and prolongs the reproductive years. If this brake did not exist, all eggs would awaken rapidly and the reserve could be depleted at a very early age.

Its second key role is to regulate the sensitivity of the growing small follicles to the hormone FSH (Follicle-Stimulating Hormone). In a natural cycle, the aim is for only one egg to fully mature and ovulate each month. AMH prevents the small follicles from responding “excessively” to FSH. However, as one of them grows, this brake (AMH production) is lifted and it becomes more sensitive to FSH. In this way that follicle becomes “dominant” and continues to grow, while the others fall behind.

What aspect of ovarian reserve does the AMH test show?

This is the most commonly misunderstood point. The AMH test cannot measure the “total” number of dormant eggs a woman has had since birth. This is because those dormant follicles do not produce AMH.

What AMH measures is the state we call the “Functional Ovarian Reserve” (FOR). In other words, it shows the size of the pool of follicles that are currently active, growing, and producing AMH.

Why is this distinction so important? Because the egg-stimulating injections we use in IVF treatment also act on this “functional” and “active” pool. This is why AMH can predict so well how many eggs we will collect in IVF treatment. AMH gives us an early hint of the numerical potential of the follicle group that the medications will act upon. Therefore, while AMH is not very successful in predicting a woman’s age at menopause, it is extraordinarily successful in predicting her response to IVF treatment.

What is the difference between AMH and the Antral Follicle Count (AFC) seen on ultrasound?

AMH and Antral Follicle Count (AFC) are in fact two different markers that tell the same story. Both measure the “functional ovarian reserve” and their results usually run in parallel.

AFC is the physical counting of the small follicles with a diameter of 2–10 mm that we see in the ovaries on a vaginal ultrasound performed at the beginning of the menstrual period (usually on day 2 or 3).

We can summarize the difference between them as follows:

• AFC: It is the visual and physical measurement of the reserve. We “count” the eggs with our eyes.
• AMH: It is the biochemical (blood) measurement of the reserve. We measure the “hormonal signal” those eggs release into the bloodstream.

Both are very valuable. The practical advantage of AMH is that it is a blood test, can be performed at any time of the day or menstrual cycle, and is less affected by operator-dependent variability (such as different doctors making different counts on ultrasound).

Why is the AMH test more valuable than older tests such as FSH?

In evaluating ovarian reserve, AMH is a much more modern and reliable test than traditional tests such as FSH or estradiol (E2), which are especially measured on day 3 of the menstrual cycle. AMH has several distinct advantages over these traditional tests:

• It can be performed on any day of the cycle
• It shows less fluctuation compared to FSH
• It reveals ovarian aging much earlier
• It provides clearer and more direct information about the reserve
• It offers more consistent results from cycle to cycle

The most important difference is its “early warning” function. When ovarian reserve begins to decline, AMH is the first signal to fall. FSH, on the other hand, is a much later marker. FSH rises only after the reserve has significantly decreased, when the brain has to “shout louder” to stimulate the ovary. In other words, a fall in AMH shows the beginning of the problem, whereas a rise in FSH usually indicates a more advanced stage of the problem. For these reasons, in current IVF practice we primarily rely on the AMH test for reserve assessment.

How does AMH predict the egg response in IVF treatment?

The main and most valuable use of AMH in IVF treatment is its ability to predict the numerical response a patient will give to egg-stimulating injections. An AMH value measured before starting treatment allows us to group patients according to the expected egg yield.

• Poor Response: Low AMH levels (usually below 1.0–1.2 ng/mL) indicate a “poor ovarian response”. This means a high likelihood that only a small number of eggs (e.g. 4 or fewer) will be collected from the treatment. Very low levels (e.g. below 0.5 ng/mL) warn us that the response to treatment may be minimal (0–2 eggs) and that there is a higher risk of canceling the cycle due to insufficient development.
• Normal Response: AMH values of approximately 1.0 to 3.5 ng/mL usually indicate that a satisfactory response will be obtained with standard treatment protocols and that an adequate number of eggs can be collected.
• High Response: High AMH levels (usually above 3.5 ng/mL) are a strong predictor that there will be an “excessive” response to treatment (e.g. more than 15–20 eggs).

This prediction changes the treatment approach from being “reactive” (intervene when a problem occurs) to “proactive” (foresee the problem and take precautions). By knowing the patient’s potential from the outset, we can now individualize the medication dose and treatment protocol.

What risks are present in patients with high AMH levels and what measures are taken?

A high AMH level (e.g. > 3.5 ng/mL) means a potential for “excessive egg response”. This is the most important risk factor for a serious and potentially dangerous complication called Ovarian Hyperstimulation Syndrome (OHSS). OHSS is characterized by the ovaries over-responding to treatment, fluid accumulation in the abdomen, and blood concentration. This is a particularly significant risk in patients with Polycystic Ovary Syndrome (PCOS), whose AMH levels are already well above normal.

Being able to identify these high-risk patients even before starting treatment thanks to the AMH test has created a revolution in IVF safety. When a high AMH is detected, the following strategies are used to minimize the risk of OHSS.

• Starting with a low medication dose
• Preference for an antagonist protocol (short protocol)

Instead of the standard trigger injections that precipitate the risk of OHSS, the use of a “safer trigger injection” (GnRH agonist)

• The “freeze-all” strategy
• Postponing fresh embryo transfer

This AMH-guided approach has dramatically reduced the frequency and severity of OHSS. With frozen embryo transfer instead of fresh transfer, these patients both preserve their very high pregnancy chances and are completely protected from the risk of OHSS.

Does the AMH test provide information about egg or embryo quality?

The confusion on this issue needs to be clarified clearly: Absolutely not.

This is the biggest and most dangerous misconception about AMH. The AMH test shows the numerical sufficiency (quantity) of the ovarian reserve; it does not provide information about its quality (genetic competence).

The most important and essentially the only factor that determines a woman’s egg quality (that is, whether the egg is genetically healthy) is her chronological age.

We can summarize this with a simple slogan: AGE = QUALITY, AMH = NUMBER.

All scientific studies conducted have failed to find a meaningful relationship between AMH level and the genetic health of the embryo once age is taken into account.

To explain this with an example:

Consider a 28-year-old woman with a low AMH. She may yield “few” eggs in an IVF treatment (low quantity). However, because she is young, the likelihood that these few eggs are “high-quality” and genetically healthy is high.

On the other hand, consider a 41-year-old woman with a high AMH. She may yield “many” eggs in treatment (high quantity). However, because her age is advanced, the likelihood that many of these eggs are “poor quality” and genetically abnormal (aneuploid) is unfortunately high.

For this reason, it should be explained to patients very clearly that AMH is a “quantity” marker, not a “quality” marker.

What is the relationship between AMH result and live birth success?

Since AMH strongly predicts “number” but does not predict “quality”, its effect on live birth, which is the ultimate goal of IVF treatment, is indirect.

The relationship is mainly mediated through the number of eggs collected. A high AMH enables more eggs to be collected. More eggs, in turn, increase the statistical chance of finding at least one genetically healthy (euploid) embryo within this group that can lead to a live birth. In short, the more eggs we collect, the greater our chance of finding that “golden egg” among them.

However, there is an interesting detail here: Very high AMH levels may appear to lower live birth rates in IVF cycles with fresh transfer. The reason is not that these patients have poor-quality eggs, but that, to avoid the risk of OHSS, fresh transfer is not performed in that cycle and all embryos are frozen (“freeze-all”).

When looking at the whole picture, that is, the Cumulative Live Birth Rate (fresh transfer plus all frozen embryo transfers), the best prognosis is actually in these patients with high AMH and a large number of frozen embryos.

Are there other factors that affect the AMH result?

Yes, when interpreting an AMH result, certain conditions that can affect the value temporarily or permanently should be taken into account.

• Use of birth control pills (most importantly, they temporarily suppress AMH by 20–50%)
• Polycystic Ovary Syndrome (PCOS) (causes AMH to be 2–5 times higher than normal)
• Previous ovarian surgeries (especially chocolate cyst or other cyst surgeries)
• History of chemotherapy or radiotherapy
• Pregnancy and breastfeeding period (may cause temporary suppression)
• Smoking (may accelerate depletion of the reserve and lower AMH)
• Certain genetic conditions

In particular, an AMH measured while using birth control pills may not reflect a woman’s true ovarian reserve and may falsely appear low. This effect is not permanent; 2–3 months after stopping the medication, AMH levels generally return to their true baseline.

Does the AMH test indicate the chance of conceiving naturally?

Again, the clear answer is: No. This is the second most common misconception about AMH. Extensive scientific studies have shown that AMH is a very poor marker for predicting the likelihood of conceiving naturally.

The logic is simple: For natural pregnancy, it is sufficient to select and ovulate just one healthy, good-quality egg each month. Even if the total egg reserve (AMH) is very low, this “monthly egg selection” process may continue efficiently until menopause.

Therefore, the clinical value of AMH is almost entirely limited to assisted reproductive technologies such as IVF. Because in IVF the goal is not to obtain “one” egg but “many” eggs.

What does a low AMH result mean? Is it necessary to panic?

Receiving a low AMH result can understandably be anxiety-provoking, especially at a young age. However, this is not a diagnosis of “infertility” or a label of “you will never have a child”.

A low AMH indicates that the ovarian reserve has decreased in number. In terms of “fertility potential”, this means that time is moving faster.

In terms of IVF treatment, it means that a “poor response” to treatment is expected, that is, a small number of eggs will be collected. This may mean that more than one treatment cycle (egg retrieval procedure) will be required to find a healthy embryo.

A low AMH should be seen not as a reason for panic but as a signal to “take action”. It is an important warning not to postpone plans of having children and, when necessary, to turn without delay to effective treatments such as IVF.

Is the AMH test alone sufficient for an accurate fertility assessment?

Absolutely not. Although AMH is a very powerful tool, it should never be used alone to make definitive decisions about a woman’s fertility. A comprehensive and accurate assessment requires assembling multiple pieces of a puzzle.

An accurate fertility assessment and IVF planning should be based on the following three main pillars:

• Patient’s Age: The most important factor determining quality.
• AMH Level: The biochemical indicator of egg number (quantity).
• Antral Follicle Count (AFC): Visual confirmation of egg number by ultrasound.

When these three factors are consistent with each other (e.g. advanced age + low AMH + low AFC), they draw a clearer picture, whereas when they are conflicting (e.g. young age + low AMH + normal AFC), they require more careful interpretation. Treatment planning can be carried out correctly and responsibly only when this holistic approach is adopted.

Frequently Asked Questions